|
US5844095A
(en)
|
1991-06-27 |
1998-12-01 |
Bristol-Myers Squibb Company |
CTLA4 Ig fusion proteins
|
|
EP0699236B2
(en)
|
1993-05-19 |
2006-06-14 |
Schering Corporation |
Purified mammalian flt3 ligands and agonists and antagonists thereof
|
|
SK782002A3
(en)
*
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
EP1908780B1
(en)
|
2000-01-03 |
2012-08-15 |
The Trustees Of The University Of Pennsylvania |
Novel chimeric proteins and methods for using the same
|
|
US20110041190A1
(en)
|
2002-10-31 |
2011-02-17 |
Tykocinski Mark L |
Novel chimeric proteins
|
|
US7696168B2
(en)
|
2000-04-21 |
2010-04-13 |
Tufts Medical Center, Inc. |
G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
|
|
DE60116075T4
(de)
*
|
2000-04-25 |
2007-06-06 |
Immunex Corp., Thousand Oaks |
Behandlung von tumoren mit photodynamischer therapie
|
|
WO2002066044A2
(en)
*
|
2000-10-24 |
2002-08-29 |
Immunex Corporation |
Method for dendritic cells based immunotherapy of tumors using combination therapy
|
|
EP1456652A4
(en)
|
2001-11-13 |
2005-11-02 |
Dana Farber Cancer Inst Inc |
IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
|
|
BRPI0406605B8
(pt)
|
2003-11-13 |
2021-05-25 |
Hanmi Holdings Co Ltd |
conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
|
|
CN101198621A
(zh)
*
|
2005-01-25 |
2008-06-11 |
阿波罗生命科学有限公司 |
分子及其嵌合分子
|
|
JP2006345852A
(ja)
|
2005-06-16 |
2006-12-28 |
Virxsys Corp |
抗体複合体
|
|
WO2007133811A2
(en)
|
2006-05-15 |
2007-11-22 |
Viral Logic Systems Technology Corp. |
Cd47 related compositions and methods for treating immunological diseases and disorders
|
|
CN105837690A
(zh)
|
2006-06-12 |
2016-08-10 |
新兴产品开发西雅图有限公司 |
具有效应功能的单链多价结合蛋白
|
|
CA2656923A1
(en)
|
2006-06-21 |
2007-12-27 |
Genentech, Inc. |
Crystal structures of ox40l and ox40l complexed with ox40 receptor
|
|
US20100150931A1
(en)
|
2006-11-22 |
2010-06-17 |
Centre Hospitalier De L'universite De Montreal |
Novel receptor for cd40l and uses thereof
|
|
PT3056515T
(pt)
|
2008-01-15 |
2019-07-19 |
Univ Leland Stanford Junior |
Métodos para manipulação da fagocitose mediada por cd47
|
|
US20090226435A1
(en)
|
2008-03-08 |
2009-09-10 |
Sanjay Khare |
Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
|
|
EP2111869A1
(en)
|
2008-04-23 |
2009-10-28 |
Stichting Sanquin Bloedvoorziening |
Compositions and methods to enhance the immune system
|
|
CN102137869B
(zh)
|
2008-06-30 |
2018-07-06 |
宾夕法尼亚大学 |
Fn14/TRAIL融合蛋白
|
|
JP2011526794A
(ja)
|
2008-07-02 |
2011-10-20 |
エマージェント プロダクト デベロップメント シアトル, エルエルシー |
TGF−βアンタゴニスト多重標的結合性分子
|
|
US8080246B2
(en)
|
2008-11-26 |
2011-12-20 |
Five Prime Therapeutics, Inc. |
Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
|
|
BRPI0923442A2
(pt)
|
2008-12-19 |
2016-01-12 |
Novartis Ag |
polipeptídeos solúveis para uso em tratamento de distúrbio autoimunes e inflamatórios.
|
|
US9221895B2
(en)
|
2009-03-13 |
2015-12-29 |
The Trustees Of The University Of Pennsylvania |
OX40/TRAIL fusion proteins
|
|
US8993524B2
(en)
|
2010-03-05 |
2015-03-31 |
The Johns Hopkins University |
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
|
|
EP2621514B1
(en)
|
2010-09-28 |
2016-09-21 |
KAHR Medical (2005) Ltd |
Compositions and methods for treatment of hematological malignancies
|
|
CN103261217B
(zh)
|
2010-11-11 |
2017-04-26 |
港大科桥有限公司 |
可溶性 pd‑1变体、融合构建体及其用途
|
|
EP3415528B1
(en)
|
2011-04-13 |
2021-05-26 |
Bristol-Myers Squibb Company |
Fc fusion proteins comprising novel linkers or arrangements
|
|
WO2012162565A2
(en)
|
2011-05-25 |
2012-11-29 |
Cel-Sci Corporation |
Method for inducing an immune response for treatment of cancer and autoimmune diseases or conditions
|
|
CN102850458B
(zh)
|
2011-06-28 |
2014-10-01 |
华博生物医药技术(上海)有限公司 |
新型重组双功能融合蛋白及其制法和用途
|
|
MX2014001222A
(es)
|
2011-07-29 |
2014-09-15 |
Univ Pennsylvania |
Receptores coestimuladores de cambio.
|
|
US9828432B2
(en)
|
2012-02-06 |
2017-11-28 |
Providence Health & Services—Oregon |
Cancer treatment and monitoring methods using OX40 agonists
|
|
PL3489254T3
(pl)
|
2012-04-30 |
2023-01-30 |
Biocon Limited |
Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania
|
|
EP2850106B1
(en)
|
2012-05-18 |
2022-03-23 |
Aptevo Research and Development LLC |
Bispecific scfv immunofusion (bif) binding to cd123 and cd3
|
|
CN112587671A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
WO2014043215A1
(en)
*
|
2012-09-11 |
2014-03-20 |
The Texas A&M University System |
Bi-specifc diabodies for masking and targeting vaccines
|
|
ME03550B
(me)
|
2012-12-17 |
2020-07-20 |
Trillium Therapeutics Inc |
Lečenje cd47+ obolelih ćelija sa sirp alfa-fc fuzijama
|
|
EP2941438A1
(en)
|
2013-01-01 |
2015-11-11 |
Kahr Medical Ltd. |
Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof
|
|
EP2948475A2
(en)
|
2013-01-23 |
2015-12-02 |
AbbVie Inc. |
Methods and compositions for modulating an immune response
|
|
EP2951199A4
(en)
|
2013-01-31 |
2016-07-20 |
Univ Jefferson |
Fusion proteins for the modulation of regulatory and effector T cells
|
|
EP2951209A4
(en)
|
2013-01-31 |
2016-06-22 |
Univ Jefferson |
CD40 OX40 AGONIST FUSION PROTEIN AND USES THEREOF
|
|
WO2015116178A1
(en)
|
2014-01-31 |
2015-08-06 |
Thomas Jefferson University |
Fusion proteins for modulating regulatory and effector t cells
|
|
EP2950814A4
(en)
|
2013-01-31 |
2016-06-08 |
Univ Jefferson |
FUSION PROTEINS BASED ON PD-L1 AND PD-L2 AND USES THEREOF
|
|
WO2014121093A1
(en)
|
2013-01-31 |
2014-08-07 |
Thomas Jefferson University |
Fusion proteins that facilitate cancer cell destruction
|
|
IL298125A
(en)
|
2013-02-26 |
2023-01-01 |
Memorial Sloan Kettering Cancer Center |
Preparations and methods for immunotherapy
|
|
MY186864A
(en)
|
2013-03-12 |
2021-08-26 |
Biocon Ltd |
Fusion immunomodulatory proteins and methods for making same
|
|
SMT202300039T1
(it)
|
2013-09-13 |
2023-03-17 |
Beigene Switzerland Gmbh |
Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
|
|
US10196435B2
(en)
|
2013-11-18 |
2019-02-05 |
University Of Southern California |
OX40L fusion protein for the immunotherapy of tumors of veterinary animals
|
|
MX2016007965A
(es)
|
2013-12-17 |
2016-10-28 |
Genentech Inc |
Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1.
|
|
AU2015205530B8
(en)
|
2014-01-13 |
2019-09-19 |
Pieris Pharmaceuticals Gmbh |
Multi-specific polypeptide useful for localized tumor immunomodulation
|
|
WO2015112534A2
(en)
|
2014-01-21 |
2015-07-30 |
Medimmune, Llc |
Compositions and methods for modulating and redirecting immune responses
|
|
JP6355032B2
(ja)
|
2014-03-24 |
2018-07-11 |
イミューンオンコ バイオファーマシューティカルズ (シャンハイ) カンパニー リミテッド |
新規組換え二機能性融合タンパク質、それらの調製および使用
|
|
CN106456734A
(zh)
|
2014-05-29 |
2017-02-22 |
免疫医疗有限责任公司 |
Ox40l融合蛋白及其用途
|
|
EP3160497A4
(en)
|
2014-06-27 |
2018-01-17 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Conjugates for immunotherapy
|
|
WO2016023040A1
(en)
|
2014-08-08 |
2016-02-11 |
Alexo Therapeutics International |
Sirp-alpha variant constructs and uses thereof
|
|
JP6640834B2
(ja)
|
2014-08-11 |
2020-02-05 |
デリニア, インコーポレイテッド |
自己免疫疾患の処置のために調節性t細胞を選択的に活性化させる改変il−2変異体
|
|
ES2751915T5
(es)
|
2014-08-15 |
2022-12-23 |
Merck Patent Gmbh |
Proteínas de fusión de inmunoglobulina con SIRP alfa
|
|
CN106999583A
(zh)
|
2014-11-17 |
2017-08-01 |
豪夫迈·罗氏有限公司 |
包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
|
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
MA41460A
(fr)
|
2015-02-03 |
2017-12-12 |
Oncomed Pharm Inc |
Agents de liaison à la tnfrsf et leurs utilisations
|
|
US10046047B2
(en)
|
2015-02-06 |
2018-08-14 |
Heat Biologics, Inc. |
Vector co-expressing vaccine and costimulatory molecules
|
|
WO2016166139A1
(en)
|
2015-04-14 |
2016-10-20 |
Eberhard Karls Universität Tübingen |
Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
|
|
DK3298043T3
(da)
|
2015-05-18 |
2021-02-15 |
Ab Initio Biotherapeutics Inc |
SIRP-polypeptidsammensætninger og fremgangsmåder til anvendelse
|
|
RU2740672C2
(ru)
|
2015-08-07 |
2021-01-19 |
ЭйЭлЭкс Онколоджи Инк. |
Конструкции, имеющие sirp-альфа домен или его вариант
|
|
SG10201913573UA
(en)
*
|
2015-10-01 |
2020-03-30 |
Heat Biologics Inc |
Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
|
|
JP6898325B2
(ja)
*
|
2015-12-08 |
2021-07-07 |
ユニバーシティ−インダストリー・ファンデーション・ヨンセイ・ユニバーシティ |
GM−CSF遺伝子;Flt3L−TRAIL融合遺伝子;TGF−βの発現を抑制するshRNA;およびHSP発現を抑制するshRNAを含む抗腫瘍組成物
|
|
EP3529276A4
(en)
|
2016-10-21 |
2020-06-17 |
Arch Oncology, Inc. |
CD47 THERAPEUTIC ANTIBODIES
|